Full Text:   <1079>

Summary:  <308>

CLC number: R543.3

On-line Access: 2017-01-03

Received: 2016-07-21

Revision Accepted: 2016-10-20

Crosschecked: 2016-12-14

Cited: 0

Clicked: 1565

Citations:  Bibtex RefMan EndNote GB/T7714


Xiao-yan Nie


-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2017 Vol.18 No.1 P.37-47


Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity

Author(s):  Xiao-yan Nie, Jun-lei Li, Yong Zhang, Yang Xu, Xue-li Yang, Yu Fu, Guang-kai Liang, Yun Lu, Jian Liu, Lu-wen Shi

Affiliation(s):  School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China; more

Corresponding email(s):   niexy@bjmu.edu.cn, drjianliu@163.com, shilu@bjmu.edu.cn

Key Words:  P2RY12, CYP2C19, Haplotype, Single nucleotide polymorphism (SNP), Clopidogrel, Thromboelastography

Xiao-yan Nie, Jun-lei Li, Yong Zhang, Yang Xu, Xue-li Yang, Yu Fu, Guang-kai Liang, Yun Lu, Jian Liu, Lu-wen Shi. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity[J]. Journal of Zhejiang University Science B, 2017, 18(1): 37-47.

@article{title="Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity",
author="Xiao-yan Nie, Jun-lei Li, Yong Zhang, Yang Xu, Xue-li Yang, Yu Fu, Guang-kai Liang, Yun Lu, Jian Liu, Lu-wen Shi",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity
%A Xiao-yan Nie
%A Jun-lei Li
%A Yong Zhang
%A Yang Xu
%A Xue-li Yang
%A Yu Fu
%A Guang-kai Liang
%A Yun Lu
%A Jian Liu
%A Lu-wen Shi
%J Journal of Zhejiang University SCIENCE B
%V 18
%N 1
%P 37-47
%@ 1673-1581
%D 2017
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1600333

T1 - Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity
A1 - Xiao-yan Nie
A1 - Jun-lei Li
A1 - Yong Zhang
A1 - Yang Xu
A1 - Xue-li Yang
A1 - Yu Fu
A1 - Guang-kai Liang
A1 - Yun Lu
A1 - Jian Liu
A1 - Lu-wen Shi
J0 - Journal of Zhejiang University Science B
VL - 18
IS - 1
SP - 37
EP - 47
%@ 1673-1581
Y1 - 2017
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1600333

Objective: To investigate a possible association between common variations of the P2RY12 and the residual clopidogrel on-treatment platelet reactivity after adjusting for the influence of CYP2C19 tested by thromboelastography (TEG). Methods: One hundred and eighty patients with acute coronary syndrome (ACS) treated with clopidogrel and aspirin were included and platelet function was assessed by TEG. Five selected P2RY12 single nucleotide polymorphisms (SNPs; rs6798347, rs6787801, rs6801273, rs6785930, and rs2046934), which cover the common variations in the P2RY12 gene and its regulatory regions, and three CYP2C19 SNPs (*2,*3,*17) were genotyped and possible haplotypes were analyzed. Results: The high on-treatment platelet reactivity (HTPR) prevalence defined by a platelet inhibition rate <30% by TEG in adenosine diphosphate (ADP)-channel was 69 (38.33%). Six common haplotypes were inferred from four of the selected P2RY12 SNPs (denoted H0 to H5) according to the linkage disequilibrium R square (except for rs2046934). haplotype H1 showed a significantly lower incidence of HTPR than the reference haplotype (H0) in the total study population while haplotypes H1 and H2 showed significantly lower incidences of HTPR than H0 in the nonsmoker subgroup after adjusting for CYP2C19 effects and demographic characteristics. rs2046934 (T744C) did not show any significant association with HTPR. Conclusions: The combination of common P2RY12 variations including regulatory regions rather than rs2046934 (T744C) that related to pharmacodynamics of clopidogrel in patients with ACS was independently associated with residual on-clopidogrel platelet reactivity. This is apart from the established association of the CYP2C19. This association seemed more important in the subgroup defined by smoking.


方法:连续入选180例接受氯吡格雷药物治疗的急性冠脉综合征患者,利用血栓弹力图法检测患者用药后血小板反应性,将用药后血小板抑制率<30%定义为血小板高反应性(HTPR)。用多重连接酶检测反应(LDR)技术,对覆盖P2RY12调控基因在内的五个基因位点(rs6798347、 rs6787801、rs6801273、rs6785930和rs2046934)以及CYP2C19常见的三个等位基因(*2、*3和*17)进行基因分型。根据连锁不平衡系数和基因分布频率进行单倍体分析,观察在校正CYP2C19基因多态性影响后,不同P2RY12单倍体分型对氯吡格雷用药后HTPR的影响。


Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1]Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et al., 2005. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb. Res., 116(6):491-497.

[2]Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et al., 2007. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol., 49(14):1505-1516.

[3]Beinart, S.C., Kolm, P., Veledar, E., et al., 2005. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol., 46(5):761-769.

[4]Bierend, A., Rau, T., Maas, R., et al., 2008. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. Br. J. Clin. Pharmacol., 65(4):540-547.

[5]Bliden, K.P., DiChiara, J., Tantry, U.S., et al., 2007. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol., 49(6):657-666.

[6]Bliden, K.P., Dichiara, J., Lawal, L., et al., 2008. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J. Am. Coll. Cardiol., 52(7):531-533.

[7]Bonello, L., Bonello-Palot, N., Armero, S., et al., 2010. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb. Res., 125(4):e167-e170.

[8]Cavallari, U., Trabetti, E., Malerba, G., et al., 2007. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med. Genet., 8:59.

[9]Chen, Y., Huang, X., Tang, Y., et al., 2014. GW25-e3303 Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol., 64(16):C203.

[10]Cicko, S., Lucattelli, M., Müller, T., et al., 2010. Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J. Immunol., 185(1):688-697.

[11]Cuisset, T., Frere, C., Quilici, J., et al., 2007. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb. Res., 120(6):893-899.

[12]Emergency Medical Branch of Chinese Medical Doctor Association, Cardiovascular Epidemiology Branch of Chinese Medical Association, Laboratory Medicine Brance of Chinese Medical Association, 2016. Emergency rapid diagnosis and treatment of guidelines acute coronary syndrome. Chin. J. Emerg. Med., 25(4):397-404 (in Chinese).

[13]Fontana, P., Gaussem, P., Aiach, M., et al., 2003. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation, 108(24):2971-2973.

[14]Gremmel, T., Steiner, S., Seidinger, D., et al., 2009. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb. Res., 124(5):588-591.

[15]Gurbel, P.A., Bliden, K.P., Logan, D.K., et al., 2013. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J. Am. Coll. Cardiol., 62(6):505-512.

[16]Hochholzer, W., Trenk, D., Mega, J.L., et al., 2011. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am. Heart J., 162(3):518-526.e5.

[17]Jana, U., Ludek, S., Jana, K., et al., 2014. Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy. Genet. Test. Mol. Biomarkers, 18(9):599-604.

[18]Jang, M.J., Jeon, Y.J., Min, K.T., et al., 2012. Polymorphisms of platelet ADP receptor P2RY12 in the risk of venous thromboembolism in the Korean population. Clin. Appl. Thromb Hemost., 18(4):416-420.

[19]Jeong, Y.H., Cho, J.H., Kang, M.K., et al., 2010. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. Thromb. Res., 126(4):e334-e338.

[20]Kar, R., Meena, A., Yadav, B.K., et al., 2013. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets, 24(4):297-302.

[21]Kim, K.A., Song, W.G., Lee, H.M., et al., 2013. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Thromb Res., 132(2):221-226.

[22]Kim, Y.G., Suh, J.W., Kang, S.H., et al., 2016. Cigarette smoking does not enhance clopidogrel responsiveness after adjusting VerifyNow P2Y12 reaction unit for the influence of hemoglobin level. JACC Cardiovasc. Interv., 9(16):1680-1690.

[23]Lev, E.I., Patel, R.T., Guthikonda, S., et al., 2007. Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel. Thromb. Res., 119(3):355-360.

[24]Levine, G.N., Bates, E.R., Bittl, J.A., et al., 2016. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/ AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non– ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation, 134(10):e123-e155.

[25]Li, X.Q., Ma, N., Li, X.G., et al., 2016. Association of PON1, P2Y12 and COX1 with recurrent ischemic events in patients with extracranial or intracranial stenting. PLoS ONE, 11(2):e0148891.

[26]Liu, J., Nie, X.Y., Zhang, Y., et al., 2015. CYP2C19*2 and other allelic variants affecting platelet response to clopidogrel tested by thrombelastography in patients with acute coronary syndrome. Chin. Med. J. (Engl.), 128(16): 2183-2188.

[27]Malek, L.A., Kisiel, B., Spiewak, M., et al., 2008. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ. J., 72(7):1165-1169.

[28]Mega, J.L., Close, S.L., Wiviott, S.D., et al., 2010a. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet, 376(9749):1312-1319.

[29]Mega, J.L., Simon, T., Collet, J.P., et al., 2010b. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA, 304(16):1821-1830.

[30]Namazi, S., Kojuri, J., Khalili, A., et al., 2012. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochem. Pharmacol., 83(7):903-908.

[31]Oestreich, J.H., Steinhubl, S.R., Ferraris, S.P., et al., 2014. Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. J. Thromb. Thrombolysis, 38(3):372-379.

[32]Patti, G., Polacco, M., Taurino, E., et al., 2016. Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study. J. Thromb. Thrombolysis, 41(4):648-653.

[33]Peng, L., Zhang, L., Yang, J., et al., 2015. Joint effects of CYP2C19*2 and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome. Int. J. Cardiol., 180(1):196-198.

[34]Price, M.J., Nayak, K.R., Barker, C.M., et al., 2009. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am. J. Cardiol., 103(10):1339-1343.

[35]Rudež, G., Pons, D., Leebeek, F., et al., 2008. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum. Mutat., 29(3):375-380.

[36]Rudež, G., Bouman, H.J., van Werkum, J.W., et al., 2009. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ. Cardiovasc. Genet., 2(5):515-521.

[37]SIGN, 2016. SIGN 148 Acute Coronary Syndrome. Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh. http://www.sign.ac.uk [June 15, 2016].

[38]Section of Interventional Cardiology of Chinese Society of Cardiology of Chinese Medical Association, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, Editorial Board of Chinese Journal of Cardiology, 2016. Chinese guideline for percutaneous coronary intervention (2016). Chin. J. Cardiol., 44(5):382-400 (in Chinese).

[39]Shalia, K.K., Shah, V.K., Pawar, P., et al., 2013. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response. Indian Heart J., 65(2):158-167.

[40]Shanker, G., Kontos, J.L., Eckman, D.M., et al., 2006. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J. Thromb. Thrombolysis, 22(3):213-220.

[41]Sibbing, D., Bernlochner, I., Schulz, S., et al., 2012. The impact of smoking on the antiplatelet action of clopidogrel in non-ST-elevation myocardial infarction patients: results from the ISAR-REACT 4 platelet substudy. J. Thromb. Haemost., 10(10):2199-2202.

[42]Simon, T., Bhatt, D.L., Bergougnan, L., et al., 2011. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin. Pharmacol. Ther., 90(2):287-295.

[43]Smith, S.M., Judge, H.M., Peters, G., et al., 2006. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets, 17(4):250-258.

[44]Staritz, P., Kurz, K., Stoll, M., et al., 2009. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int. J. Cardiol., 133(3):341-345.

[45]Tang, X.F., Han, Y.L., Zhang, J.H., et al., 2015. Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel. Chin. Med. J. (Engl.), 128(6):774-779.

[46]Tantcheva-Poór, I., Zaigler, M., Rietbrock, S., et al., 1999. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics, 9(2):131-144.

[47]Ueno, M., Ferreiro, J.L., Desai, B., et al., 2012. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc. Interv., 5(3):293-300.

[48]Yousef, A.M., Arafat, T., Bulatova, N.R., et al., 2008. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. J. Clin. Pharm. Ther., 33(4):439-449.

[49]Yusuf, S., Zhao, F., Mehta, S.R., et al., 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 345(7):494-502.

[50]Zee, R.Y., Michaud, S.E., Diehl, K.A., et al., 2008. Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. Atherosclerosis, 197(2):694-699.

[51]Zhang, J.H., Wang, J., Tang, X.F., et al., 2016. Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets, 27(1):75-79.

[52]Zoheir, N., Abd Elhamid, S., Abulata, N., et al., 2013. P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting. Blood Coagul. Fibrinolysis, 24(5):525-531.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE